Answer
In pooled controlled Phase 3 adult trials of tedizolid phosphate 200 mg once daily for 6 days, the most frequently reported adverse reactions were nausea (6.9%), headache (3.5%), diarrhoea (3.2%) and vomiting (2.3%), generally mild to moderate in severity.
Sources for this answer
- Sivextro 200 mg powder for concentrate for solution for infusionMerck Sharp & Dohme (UK) Limited · emc · SmPC §4.8 Undesirable effects · Version 15Document updated
Sources checked